Sponsors (4)
The bill extends and increases support for the national cord blood and transplant programs and modernizes standards and authorities to improve safety and adoption of new technologies, but it does so with time-limited funding, greater centralized discretion that may reduce available units and raise donor/bank uncertainty, and a modest ongoing cost to taxpayers.
Patients needing cell and bone marrow transplants and transplant centers get multi-year funding continuity through FY2027–FY2031, including an added $33,009,000 per year that supports transplantation services and registry operations.
Cord blood banks, hospitals, and patients benefit from clearer, updated definitions and standards for “high-quality cord blood units” and authority to include emerging technologies, improving safety, consistency, and potential availability of usable units.
The Secretary and program administrators get clearer authority to prioritize clinically useful units and adopt new technologies, which can improve matching/outcomes for transplant recipients and make program administration more adaptable.
Taxpayers bear the cost of the additional $33,009,000 per year authorized for FY2027–FY2031, increasing federal spending commitments.
The authorization and many provisions are time-limited or tied to future reauthorization (through FY2031 or by cross-reference), creating significant uncertainty after 2031 for patients, hospitals, and state programs if Congress does not act again.
Removing the statutory 150,000-unit storage target gives the Secretary discretion that could reduce the total number of stored units, potentially limiting availability for some patients who need matches.
Based on analysis of 4 sections of legislative text.
Reauthorizes funding for the national cord blood program, replaces a numeric unit target with Secretary-led inventory management, and adds transfer and quality authorities for cord blood and emergent technologies.
Official title: Reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
Introduced March 17, 2026 by John F. Reed · Last progress March 17, 2026
Reauthorizes and updates the federal cord blood / cell transplantation program by continuing and expanding annual funding, replacing a fixed numeric inventory goal with Secretary-directed inventory-management authority, and adding transfer and quality-control powers for cord blood units and emerging technologies. It adjusts statutory language and definitions to reference current clinical and FDA standards and extends the program authorization through fiscal year 2031.